Spondyloarthritis & psoriatic arthritis
Drug‐Free Remission in Early Peripheral Spondyloarthritis, Including Psoriatic Arthritis: 10‐Year Follow‐Up From the CRESPA Trial
Authors' conclusion
Remission induction with golimumab in patients with early pSpA enables achievement of sustained clinical remission in the majority of patients, with one-third of patients attaining drug-free remission. Strikingly, almost half of patients with nonpsoriatic pSpA remained in drug-free remission.
Study context
- Population
- Patients fulfilling the ASAS peripheral spondyloarthritis (pSpA) classification criteria, symptom duration ≤12 weeks, originally randomised to golimumab 50 mg every four weeks or placebo49 evaluated
- Participants
- 60 patients
- Primary endpoint
- Proportion of patients in (drug-free) clinical remission (absence of swollen joints, enthesitis, or dactylitis)
- Follow-up
- 10-year follow-up
Methodological detailsdescriptive analysis, 10-year follow-up
- Descriptive analysis
- 10-year follow-up
Primary result
As reported in the abstract
mean (±SD) 10.5 (±0.87) years
Clinical remission
81.6%
40 of 49
Longstanding drug-free remission
30.6%
15 of 49
Further findings
| Outcome | Values | OR for achieving drug-free remission (95% CI) | |
|---|---|---|---|
| Drug-free remission by psoriasis at baseline · 10-year follow-upNo psoriasis at baselinevs Psoriasis at baseline | Nonpsoriatic pSpA 48.1% | 9.1 (1.8–50) | |
| 0.050.21520OR for achieving drug-free remission (log scale) |
- Drug-free remission by psoriasis at baseline: 13 of 27
Baseline predictors of remission (sex, age, HLA-B27 positivity, psoriasis, initial treatment allocation) · 10-year follow-up
- Remission not linked to baseline characteristics like sex, age, HLA-B27 positivity, psoriasis, or initial treatment allocation
Health-related quality of life and physical function · 10-year follow-up
- Significantly better in patients in remission
Original publication
Drug‐Free Remission in Early Peripheral Spondyloarthritis, Including Psoriatic Arthritis: 10‐Year Follow‐Up From the CRESPA Trial. Arthritis Rheumatol. Published 21 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →